Metformin in reproductive health, pregnancy and gynaecological cancer: established and emerging indications
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Metformin is an effective oral anti-hyperglycaemic drug used as first-line medical treatment for type 2 diabetes. It improves systemic hyperglycaemia by reducing hepatic glucose production and enhancing peripheral insulin sensitivity. It also stimulates fat oxidation and reduces fat synthesis and storage. The molecular mechanism of this drug is thought to be secondary to its actions on the mitochondrial respiratory chain. METHODS: This paper reviews the relevant literature (research articles up to October 2013) on the use of metformin in infertility, polycystic ovary syndrome (PCOS), pregnancy and gynaecological cancers. We present a comprehensive discussion of the evidence supporting the efficacy of metformin in these clinical conditions. RESULTS: Metformin is used clinically off-label in the management of hirsutism, acne and insulin resistance in PCOS, although the evidence for anti-androgenic effects is inconsistent. Metformin is also used to improve ovulation in women with PCOS both alone and in combination with clomiphene citrate. Trial findings are conflicting but metformin treatment in IVF/ICSI cycles may reduce the risk of ovarian hyperstimulation syndrome and increase live birth rates. Metformin also appears to be effective and safe for the treatment of gestational diabetes mellitus (GDM), particularly for overweight and obese women. Studies have shown that metformin is safe in pregnancy and women with GDM treated with metformin have less weight gain during pregnancy than those treated with insulin. One study with a 2-year follow-up demonstrated that babies born to women treated with metformin also developed less visceral fat, making them less prone to insulin resistance in later life. These findings have sparked interest in the use of metformin for pregnant, obese, non-diabetic women. On-going clinical trials are underway to determine if women treated prophylactically with metformin have a reduced incidence of GDM and demonstrate less weight gain during pregnancy. The hypothesis in these studies is that babies born to obese women on prophylactic metformin will also have better outcomes. Epidemiological studies have linked metformin exposure to a decreased risk of cancer. Pre-clinical experiments report that metformin has a growth-static effect on several cancers, including endometrial cancer, which may be partly due to the effect of metformin on the PI3K/AKT/mTOR signal transduction pathway. A number of on-going early phase clinical trials aim to explore the anti-cancer effects of metformin and investigate its potential as a chemopreventative or adjuvant treatment. CONCLUSIONS: Obesity is on the rise in developing countries and is strongly linked to several reproductive health problems, including PCOS, GDM and endometrial cancer. Traditional lifestyle measures aimed at weight reduction are challenging to implement and maintain. Metformin may be a valuable alternative to, or adjunct for, modifying the toxic effects of obesity in these populations. This review will appraise the evidence for the use of metformin for the prevention and treatment of adverse health outcomes in obstetrics and gynaecology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 1×
“…in patients with impaired glucose tolerance by as much as 31% (95% confidence interval (CI) 17 –43) when compared with placebo, although lifestyle interventions that achieve weight loss and regular exercise are even more effective (58% reduction in risk, 95% CI 48– 66) (Knowler et al., 2002).”
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
Renehan, A. G., Tyson, M., Egger, M., Heller, R. F., & Zwahlen, M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60269-x · Cited by 5,219
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919 · cited 1×
“Metformin is the preferred and most cost-effective first-line oral therapy for the treatment of T2DM (Nathan et al., 2009; Inzucchi et al., 2012) and is usually well tolerated and not complicated by hypoglycaemia .”
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · cited 1×
“A flurry of prospective observational studies suggested that patients with T2DM taking metformin were not only at lower risk of developing cancer (Libby et al., 2009) but were also less likely to die from it (Evans et al., 2005).”
OWEN, M. R., DORAN, E., & HALESTRAP, A. P. (2000) · Biochemical Journal · doi:10.1042/bj3480607 · Cited by 2,157 · cited 1×
“Metformin inhibits the mitochondrial respiratory complex I (El-Mir et al., 2000; Owen et al., 2000), leading to reduced oxidative phosphorylation and ATP production.”
Insulin and insulin-like growth factor signalling in neoplasia
Pollak, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2536 · Cited by 2,059 · cited 1×
“3) (Pollak, 2008).”
Fauser, B. C. J. M., Tarlatzis, B. C., Rebar, R. W., Legro, R. S., Balen, A. H., Lobo, R., Carmina, E., Chang, J., Yildiz, B. O., Laven, J. S. E., et al. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.09.024 · Cited by 1,976 · cited 1×
“Cardiovascular risk factors for ischaemic heart disease and stroke include obesity, insulin resistance, glucose intolerance, diabetes, hypertension, dyslipidemia (in particular raised serum triglycerides) and various markers of inflammation (Fauser et al., 2012).”
Self-citationRamachandran, A., Snehalatha, C., Mary, S., Mukesh, B., Bhaskar, A. D., Vijay, V., & Indian Diabetes Prevention Programme (IDPP) (2006) · Diabetologia · doi:10.1007/s00125-005-0097-z · Cited by 1,881
The Mitochondrial Carnitine Palmitoyltransferase System — From Concept to Molecular Analysis
McGarry, J. D., & Brown, N. F. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00001.x · Cited by 1,616 · cited 1×
“Its activation by metformin decreases lipid synthesis, increases fatty acid oxidation and inhibits gluconeogenesis (McGarry and Brown, 1997; Li et al., 2011).”
Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes
The Look AHEAD Research Group (2007) · Diabetes Care · doi:10.2337/dc07-0048 · Cited by 1,522 · cited 1×
“Lifestyle interventions that reverse or reduce obesity have a beneficial effect on glycaemic control (Pi-Sunyer et al., 2007) but are limited by poor compliance and high relapse rates.”
El-Mir, M.-Y., Nogueira, V., Fontaine, E., Avéret, N., Rigoulet, M., & Leverve, X. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.223 · Cited by 1,399 · cited 1×
“Metformin inhibits the mitochondrial respiratory complex I (El-Mir et al., 2000; Owen et al., 2000), leading to reduced oxidative phosphorylation and ATP production.”
Metformin versus insulin for the treatment of gestational diabetes
Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707193 · Cited by 1,291 · cited 8×
“Metformin was well tolerated in all of the studies with around 2–7% unable to tolerate it (Rowan et al., 2008; Balani et al., 2009; Niromanesh et al., 2012).”
InfluentialMetabolic effects of metformin in non-insulin-dependent diabetes mellitus
Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., & Gerich, J. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330903 · Cited by 1,148 · cited 2×
“Metformin treatment combats both of these effects by increasing insulin sensitivity and reducing basal hepatic glucose output (Catalano et al., 1991; Stumvoll et al., 1995) (Figs 1 and 2).”
The insulin and insulin-like growth factor receptor family in neoplasia: an update
Pollak, M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3215 · Cited by 1,116
Hirsch, H. A., Iliopoulos, D., Tsichlis, P. N., & Struhl, K. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2994 · Cited by 1,115 · cited 2×
“…Anti-cancer drug Treatment † Improves efficacy of existing chemotherapy † Overcomes chemoresistance † Inhibits re-emergence of cancer stem cells Hanna et al. (2012) Hirsch et al. (2009) Abbreviations: AMP-activated kinase (AMPK), chemokine (CC-motif) ligand 2 (CCL2), cytochrome P450c17 enzyme…”
Moran, L. J., Misso, M. L., Wild, R. A., & Norman, R. J. (2010) · Human Reproduction Update · doi:10.1093/humupd/dmq001 · Cited by 1,108
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N., & Pollak, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1500 · Cited by 1,048
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome
Legro, R. S., Barnhart, H. X., Schlaff, W. D., Carr, B. R., Diamond, M. P., Carson, S. A., Steinkampf, M. P., Coutifaris, C., McGovern, P. G., Cataldo, N. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063971 · Cited by 1,027
New Users of Metformin Are at Low Risk of Incident Cancer
Libby, G., Donnelly, L. A., Donnan, P. T., Alessi, D. R., Morris, A. D., & Evans, J. M. M. (2009) · Diabetes Care · doi:10.2337/dc08-2175 · Cited by 996 · cited 1×
“A flurry of prospective observational studies suggested that patients with T2DM taking metformin were not only at lower risk of developing cancer (Libby et al., 2009) but were also less likely to die from it (Evans et al., 2005).”
Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
DeCensi, A., Puntoni, M., Goodwin, P., Cazzaniga, M., Gennari, A., Bonanni, B., & Gandini, S. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0157 · Cited by 918
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub4 · Cited by 893
Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner
Kalender, A., Selvaraj, A., Kim, S. Y., Gulati, P., Brûlé, S., Viollet, B., Kemp, B. E., Bardeesy, N., Dennis, P., Schlager, J. J., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.03.014 · Cited by 889
Jiralerspong, S., Palla, S. L., Giordano, S. H., Meric-Bernstam, F., Liedtke, C., Barnett, C. M., Hsu, L., Hung, M.-C., Hortobagyi, G. N., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.19.6410 · Cited by 880 · cited 1×
“…metformin were shown to have higher rates of pathological complete response to neoadjuvant chemotherapy than those not on metformin, according to a retrospective study of 2529 patients, including 68 and 87 diabetic patients taking and not taking metformin, respectively (Jiralerspong et al., 2009).”
Sahra, I. B., Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., Tanti, J. F., Le Marchand-Brustel, Y., & Bost, F. (2008) · Oncogene · doi:10.1038/sj.onc.1211024 · Cited by 861 · cited 1×
“…studies have demonstrated that metformin also inhibits mTOR through AMPK-independent pathways, including the Rag family of GTPases (Kalender et al., 2010) and the hypoxia inducible factor (HIF) target gene, regulated in development and DNA damage response 1 (REDD1) (Ben Sahra et al., 2008, 2011).”
A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome
Boomsma, C. M., Eijkemans, M. J. C., Hughes, E. G., Visser, G. H. A., Fauser, B. C. J. M., & Macklon, N. S. (2006) · Human Reproduction Update · doi:10.1093/humupd/dml036 · Cited by 852
Cellular Mechanisms for Insulin Resistance in Normal Pregnancy and Gestational Diabetes
Barbour, L. A., McCurdy, C. E., Hernandez, T. L., Kirwan, J. P., Catalano, P. M., & Friedman, J. E. (2007) · Diabetes Care · doi:10.2337/dc07-s202 · Cited by 811
Nestler, J. E., & Jakubowicz, D. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350902 · Cited by 743
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetologia · doi:10.1007/s00125-008-1157-y · Cited by 712 · cited 17×
“Treatment of T2DM aims to normalize glycaemic levels as much as possible as this has been shown specifically to reduce microvascular complications (The Diabetes Control and Complications Trial Research Group, 1993).”
InfluentialLongitudinal changes in insulin release and insulin resistance in nonobese pregnant women
Catalano, P. M., Tyzbir, E. D., Roman, N. M., Amini, S. B., & Sims, E. A. H. (1991) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(91)90012-g · Cited by 709 · cited 3×
“…of the infant † Hepatic glucose output and substrate activation of IR/ IGF1R † AMPK activation and mTOR inhibition Ali et al. (2011) Balani et al. (2009) Catalano et al. (1991) Hague et al. (2003) Lautatzis et al. (2013) Nerstedt et al. (2010) Niromanesh et al. (2012) Rowan et al. (2008)…”
Tang, T., Lord, J. M., Norman, R. J., Yasmin, E., & Balen, A. H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003053.pub5 · Cited by 698
Self-citationInsulin resistance: definition and consequences
Lebovitz, H. (2001) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2001-18576 · Cited by 664
Clark, A. M., Ledger, W., Galletly, C., Tomlinson, L., Blaney, F., Wang, X., & Norman, R. J. (1995) · Human Reproduction · doi:10.1093/oxfordjournals.humrep.a135772 · Cited by 642
Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1
Ben Sahra, I., Regazzetti, C., Robert, G., Laurent, K., Le Marchand-Brustel, Y., Auberger, P., Tanti, J.-F., Giorgetti-Peraldi, S., & Bost, F. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1769 · Cited by 616
Metformin Inhibits Proinflammatory Responses and Nuclear Factor-κB in Human Vascular Wall Cells
Isoda, K., Young, J. L., Zirlik, A., MacFarlane, L. A., Tsuboi, N., Gerdes, N., Schönbeck, U., & Libby, P. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000201938.78044.75 · Cited by 499
Hattori, Y., Suzuki, K., Hattori, S., & Kasai, K. (2006) · Hypertension · doi:10.1161/01.hyp.0000221429.94591.72 · Cited by 487 · cited 4×
“, 1995) and suppressesTNFa-inducedNFkB activation in human vein umbilical endothelial cells (Hattori et al., 2006).”
BackgroundInfluentialHolte, J., Bergh, T., Berne, C., Wide, L., & Lithell, H. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.9.7673399 · Cited by 435
Metformin in Gestational Diabetes: The Offspring Follow-Up (MiG TOFU)
Rowan, J. A., Rush, E. C., Obolonkin, V., Battin, M., Wouldes, T., & Hague, W. M. (2011) · Diabetes Care · doi:10.2337/dc11-0660 · Cited by 379
Metformin reduces endogenous reactive oxygen species and associated DNA damage
Algire, C., Moiseeva, O., Deschênes-Simard, X., Amrein, L., Petruccelli, L., Birman, E., Viollet, B., Ferbeyre, G., & Pollak, M. N. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0536 · Cited by 372 · cited 2×
“2) (Algire et al., 2012), offering an explanation for the reduced risk of cancer seen in metformin users across several epidemiological studies.”
Oteng-Ntim, E., Varma, R., Croker, H., Poston, L., & Doyle, P. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-47 · Cited by 352 · cited 2×
“Current clinical studies in obese pregnant women A number of studies have investigated the impact of lifestyle interventions on pregnancy outcomes with limited success (Oteng-Ntim et al., 2012); one such study is ongoing in the UK (UPBEAT).”
Tang, T., Glanville, J., Hayden, C. J., White, D., Barth, J. H., & Balen, A. H. (2006) · Human Reproduction · doi:10.1093/humrep/dei311 · Cited by 335
Self-citationBody mass index, hormone replacement therapy, and endometrial cancer risk: A meta-analysis
Crosbie, E. J., Zwahlen, M., Kitchener, H. C., Egger, M., & Renehan, A. G. (2010) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0832 · Cited by 321 · cited 1×
“This effect was observed even at extremely obese BMIs; indeed, a woman with a BMI of 42 has a near 10-fold increased risk of type 1 (also known as endometrioid) endometrial cancer than her normal weight counterparts (BMI 20–25 kg/m 2 ) (Crosbie et al., 2010).”
Self-citationMetformin therapy and clinical uses
Scarpello, J. H., & Howlett, H. C. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.027 · Cited by 318 · cited 1×
“Reduced atherogenesis, less oxidative stress and redistribution of visceral adiposity have all been described as potential mediators of this effect (Scarpello and Howlett, 2008).”
Vanky, E., Stridsklev, S., Heimstad, R., Romundstad, P., Skogøy, K., Kleggetveit, O., Hjelle, S., von Brandis, P., Eikeland, T., Flo, K., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0853 · Cited by 315 · cited 1×
“…a large Norwegian multicentre RCT found no improvement in these complications with continued use of metformin from late first trimester to delivery (Vanky et al., 2010), although there appeared to be a reduction in late miscarriage and preterm delivery rates, which is now the subject of a large…”
Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis
LOOMBA, R., LUTCHMAN, G., KLEINER, D. E., RICKS, M., FELD, J. J., BORG, B. B., MODI, A., NAGABHYRU, P., SUMNER, A. E., LIANG, T. J., et al. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03869.x · Cited by 299
Morin-Papunen, L., Rantala, A. S., Unkila-Kallio, L., Tiitinen, A., Hippeläinen, M., Perheentupa, A., Tinkanen, H., Bloigu, R., Puukka, K., Ruokonen, A., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3061 · Cited by 243
Ovarian hyperstimulation syndrome: pathophysiology and prevention
Nastri, C. O., Ferriani, R. A., Rocha, I. A., & Martins, W. P. (2010) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-010-9387-6 · Cited by 233
Zakikhani, M., Blouin, M.-J., Piura, E., & Pollak, M. N. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0763-9 · Cited by 213
Costello, M. F., Shrestha, B., Eden, J., Johnson, N., & Moran, L. J. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005552.pub2 · Cited by 197 · cited 1×
“…weight loss is not achieved by metformin and whilst some biochemical parameters may improve this does not translate into a significant benefit in outcomes, whether for the dermatological manifestations of hyperandrogenism (Costello et al., 2007) or the enhancement of fertility (Tang et al., 2012).”
Randomized trial of metformin vs insulin in the management of gestational diabetes
Spaulonci, C. P., Bernardes, L. S., Trindade, T. C., Zugaib, M., & Francisco, R. P. V. (2013) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2013.03.022 · Cited by 183
Sarfstein, R., Friedman, Y., Attias-Geva, Z., Fishman, A., Bruchim, I., & Werner, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061537 · Cited by 150 · cited 2×
“Metformin was shown to induce G1 cell cycle arrest, increase apoptosis and reduce human telomerase reverse transcriptase expression (Cantrell et al., 2010; Sarfstein et al., 2013).”
Cussons, A. J., Watts, G. F., Burke, V., Shaw, J. E., Zimmet, P. Z., & Stuckey, B. G. A. (2008) · Human Reproduction · doi:10.1093/humrep/den263 · Cited by 140 · cited 2×
“PCOS may also be associated with an increased risk of an individual developing T2DM, the metabolic syndrome and endometrial cancer (Cussons et al., 2008).”
Lautatzis, M.-E., Goulis, D. G., & Vrontakis, M. (2013) · Metabolism · doi:10.1016/j.metabol.2013.06.006 · Cited by 113
Insulin resistance in the control of body fat distribution: a new hypothesis
Ali, A. T., Ferris, W. F., Naran, N. H., & Crowther, N. J. (2011) · Hormone and Metabolic Research · doi:10.1055/s-0030-1269851 · Cited by 42
Cited by
Pregnancy complications in women with polycystic ovary syndrome
Palomba, S., de Wilde, M. A., Falbo, A., Koster, M. P. H., La Sala, G. B., & Fauser, B. C. J. M. (2015) · Human Reproduction Update · doi:10.1093/humupd/dmv029 · Cited by 691
“Potential advantages for the use of metformin over insulin in GDM were suggested regarding maternal weight gain during pregnancy, neonatal outcomes (including less visceral fat) and patient compliance (Rowan et al., 2008; Lautatzis et al., 2013; Sivalingam et al., 2014).”
BackgroundP53 coordinates decidual sestrin 2/AMPK/mTORC1 signaling to govern parturition timing
Deng, W., Cha, J., Yuan, J., Haraguchi, H., Bartos, A., Leishman, E., Viollet, B., Bradshaw, H. B., Hirota, Y., & Dey, S. K. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87715 · Cited by 85
Fornes, R., Simin, J., Nguyen, M. H., Cruz, G., Crisosto, N., van der Schaaf, M., Engstrand, L., & Brusselaers, N. (2022) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-022-00905-6 · Cited by 44
Metadata
- Authors
- Sivalingam, V. N., Myers, J., Nicholas, S., Balen, A. H., & Crosbie, E. J.
- Venue
- Human Reproduction Update
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-07-10
- Volume
- 20
- Issue
- 6
- Pages
- 853-868
- ISSN
- 1355-4786 (ISSN-L)
- 1460-2369
- OpenAlex
- W2161384735
- Cited by
- 108
- References
- 55
- FWCI
- 4.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.